A Phase 3 interventional study of Leuprolide Acetate 11.25 MG/ML in Central Precocious Puberty, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 13th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 4 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 79 is above the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.
The drug in this study is called leuprorelin. It is administered as a 3 month subcutaneous depot injection. Leuprorelin is used to treat children who have Central Precocious Puberty. This study will look at whether leuprorelin can stop early Central Precocious Puberty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Following conditions at Visit 1(Screening) :
Conditions related to pseudo precocious puberty, Incomplete precocious puberty, Dysfunction of pituitary, adrenal, thyroid, or reproductive glands, Growth disorders or bone diseases that could affect bone growth, Brain tumor, Pituitary adenoma
Meets the following criteria based on screening test results:
, ALT levels exceed twice the , Creatinine levels exceed 1.5 times the upper limit of normal, Bone age is above 11.5 years
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (\<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months.
Drug: Leuprolide Acetate 11.25 MG/ML
Drug page: Leuprolide
Subcutaneous injection
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L.
Time frame: 6 months
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 3 Months.
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L.
Time frame: 3 months
Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration.
Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration.
Time frame: Baseline, 3 and 6 months
Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration
Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration
Time frame: 3 and 6 months
Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration.
Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration.
Time frame: Baseline, 3 and 6 months
Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration.
Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration.
Time frame: 6 months
Average Tanner Stage at 6 months after administration, and the changes compared to before administration.
Average Tanner Stage at 6 months after administration, and the changes compared to before administration.
Time frame: 6 months
Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration.
Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Feb 2025, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide
Daewoong Pharmaceutical Co. LTD. →